Clinical trials
Patient Safety clinical trials
Below are recruiting patient safety clinical trials, each written for real people, not researchers. We’re tracking 1,317 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06564974Recruiting
Long-term safety study of Agamree for Duchenne muscular dystrophy
This study watches boys with Duchenne muscular dystrophy who are already taking Agamree (vamorolone) to see how safe it is over a long period. It helps doctors understand the medicine's effects over time.
Phoenix, ArizonaAges 2 years+ - NCT06323213RecruitingPhase 3
Testing a new asthma medicine for severe asthma
This study tests an experimental drug called 610 for people with severe asthma that is not well-controlled with standard medicines. The goal is to see if adding 610 can improve asthma control and reduce flare-ups.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06281964Enrolling by invitationPhase 3
New pill for EGFR Exon 20 lung cancer
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
Guangzhou, GuangzhouAges 18 years+ - NCT06198712RecruitingPhase 2
Testing etavopivat in children with sickle cell disease
This trial tests a new drug, etavopivat, to see how it works in children with sickle cell disease. It may help reduce painful crises and other complications.
Toronto, OntarioAges 6 months–18 years - NCT06085937RecruitingPhase 1
Ketamine for suicidal patients in the ER
This trial tests if a single dose of ketamine can quickly reduce suicidal thoughts in people who come to the emergency department. If you are having active suicidal thoughts and need inpatient care, you may be able to join.
Kansas City, KansasAges 18–65 - NCT06011889RecruitingPhase 2/Phase 3
Etanercept for treating SAPHO syndrome
This study tests if etanercept, a biologic drug that targets inflammation, safely reduces pain and disease activity in people with SAPHO syndrome.
Warsaw, Masovian VoivodeshipAges 18 years+ - NCT05860400Recruiting
Testing add-on treatment to calm artery inflammation after heart procedures
This study looks at whether a comprehensive add-on treatment—starting with immune medicine and then a heart procedure when needed—can improve outcomes for people whose coronary artery disease is getting worse quickly. It focuses on cases where inflammation is likely driving new artery blockages or worsening chest pain.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05977673RecruitingPhase 2
Tislelizumab for untreated Hodgkin lymphoma when chemo isn’t suitable
This Phase 2 trial tests tislelizumab (an immune therapy) in people with newly diagnosed classical Hodgkin lymphoma who cannot safely get standard chemotherapy. It aims to see how well the treatment works and whether it is safe for older adults and others with health limits.
Alessandria, ITAges 65 years+ - NCT05813678Recruiting
Long-term safety monitoring for Palynziq in PKU
This study tracks the long-term safety of Palynziq (pegvaliase) in people with PKU as they take the medicine over time. It may help you and other patients understand long-term side effects and whether Palynziq stays safe.
Aurora, ColoradoAges Any age - NCT05785780Enrolling by invitation
Help improve colon cancer screening for people with diabetes
This study looks for better ways to make sure people with diabetes get up-to-date colon cancer screening. If you haven’t had the recommended test on time, it may help identify barriers in primary care and improve screening follow-through.
New Brunswick, New JerseyAges 50–74 - NCT05599880RecruitingPhase 2
Bortezomib for adults with hard-to-treat immune low platelets
This Phase 2 trial tests whether bortezomib can safely increase platelet counts in adults with immune thrombocytopenia (ITP) that keeps coming back or doesn’t respond to standard treatments. It’s for people with very low platelets who still need treatment despite prior medicines.
Guri-siAges 19 years+ - NCT05462587RecruitingPhase 3
Test drug AVTX-803 for Leukocyte Adhesion Deficiency type II
This Phase 3 trial tests whether AVTX-803 can help prevent or improve infections in people with Leukocyte Adhesion Deficiency (LAD) type II. The study also checks how safe the drug is.
Rochester, MinnesotaAges 6 months–75 years - NCT05226169RecruitingPhase 3
Iron medicine plus standard therapy for advanced stomach cancer
This Phase 3 study tests whether giving ferric carboxymaltose (an IV iron treatment) helps people with advanced stomach or stomach–esophagus cancer and iron-deficiency anemia. The goal is to improve safety and how well the standard first-line cancer treatment works.
SeoulAges 19 years+ - NCT05183646RecruitingPhase 3
DMX-200 for FSGS in people taking an ARB medicine
This Phase 3 trial studies whether DMX-200 is safer and works better than placebo for people with FSGS who are already on (or can switch to) an ARB blood-pressure/kidney-protection medicine. It also looks at side effects over a long follow-up period.
Birmingham, AlabamaAges 12–80 - NCT04925479RecruitingPhase 1/Phase 2
Testing asciminib dosing and safety for teen CML patients
This early-phase study tests the right dose and safety of asciminib in children and teens with chronic myeloid leukemia (CML). It may help if your current or last CML medicine (a TKI) did not work well or caused side effects.
Indianapolis, IndianaAges 1–17 - NCT04879043RecruitingPhase 1/Phase 2
Safety study of HDP-101 for relapsed myeloma patients
This early-phase trial tests whether HDP-101 is safe and can potentially help adults with multiple myeloma that has come back or didn’t respond to standard treatments. It focuses on people who have already tried key myeloma medicines and still have measurable disease.
Atlanta, GeorgiaAges 18 years+ - NCT06244537Recruiting
MR-Linac radiation for advanced colon cancer
This trial tests a new radiation machine called MR-Linac for people with advanced colon cancer that cannot be removed by surgery. The goal is to see if it is safe and works well.
Chengdu, SichuanAges 18 years+ - NCT05113017Recruiting
Radiation after surgery for early lung cancer you can’t remove
This trial studies whether a focused form of radiation called SBRT can safely treat remaining lung cancer nodules after surgery. It may help people whose leftover tumor spots can’t be removed by more surgery, aiming to control the cancer while limiting side effects.
Changsha, HunanAges 18–75 - NCT06842199RecruitingPhase 3
Testing a new pill for moderate to severe plaque psoriasis
This trial tests an experimental drug called ICP-488 for people with moderate to severe plaque psoriasis. It aims to see if the drug can improve symptoms and is safe, and may be an option if you need stronger treatment than creams or light therapy.
Hefei, AnhuiAges 18–75 - NCT07262983RecruitingPhase 1
Baricitinib for Job syndrome with lupus or eczema
This study tests if baricitinib, a pill that changes how your immune system works, is safe and tolerable for people with Job syndrome who also have lupus-like disease or severe eczema. It might offer a new treatment option for these skin and immune problems.
Bethesda, MarylandAges 12–120 - NCT04481763RecruitingPhase 1/Phase 2
Camrelizumab plus radiation for early triple-negative breast cancer
This trial studies whether adding camrelizumab (an immunotherapy drug) to radiation can improve outcomes and be safe for people with early triple-negative breast cancer. It is designed for specific early-stage cases after breast surgery, using tumor and blood tests to match the cancer’s features.
Nanchang, JiangxiAges 18–75 - NCT07809256RecruitingPhase 3
Combination treatment for advanced lung cancer with a RET gene change
This trial tests a combination of two medicines (pembrolizumab and lenvatinib) for people with advanced non-small cell lung cancer that has a specific RET gene change. The treatment may help slow down or shrink the cancer, and the study checks how well people tolerate it.
Saint PetersburgAges 18 years+ - NCT05637086RecruitingPhase 2
Test pentoxifylline plus celecoxib for grand mal epilepsy on phenytoin
This Phase 2 study tests whether adding two medicines—pentoxifylline and celecoxib—to current phenytoin treatment is safe and may help people with grand mal (generalized) epilepsy. It focuses mainly on safety while you stay on a single epilepsy medicine.
Al MansurahAges 18–75 - NCT07757542RecruitingPhase 2
Hydrogen gas for mild cognitive impairment
This trial tests whether breathing in a small amount of hydrogen gas is safe and might help people with mild cognitive impairment. It aims to see if this simple approach could support brain health.
Ostrava, Moravian-Silesian RegionAges 50–80
Hear when a new Patient Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patient safety?
- Yes. Clin2 currently lists 1,317 recruiting patient safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patient safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patient safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.